Syntis Bio

Boston, MA · Founded 2022 · Privately Held (backing)

Developer of late-stage preclinical drugs designed for oral therapy for obesity, diabetes, and rare diseases. Syntis Bio is based in Boston, MA and was founded in 2022. It was valued at $67 million at its early-stage round in Jun 2025, the last priced event on record. It has raised $48.4 million across 3 recorded rounds; the latest was a $25 million early-stage round in Jun 2025.

PMV mark · valuation
$67.0M
Oct 2026
Priced at
its early-stage round
Jun 2025
Total raised
$48.4M
Last round
Early Stage VC
Jun 2025

Who backs Syntis Bio?

12 investors
InvestorType
National Institutes of HealthOther
Sky9 CapitalVenture capital
Safar PartnersVenture capital
Woori Venture PartnersVenture capital
BOLD Capital PartnersVenture capital
Apollo Research Labs—
Cerberus Ventures—
Cerity Partners Ventures—
Colorcon—
Mansueto Investments—
+ 2 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Syntis Bio investors

12 investors are on record for Syntis Bio, including National Institutes of Health, Sky9 Capital, Safar Partners and Woori Venture Partners. The early-stage round in Jun 2025 drew 12 investors.

Free account
More of Syntis Bio with a free account
  • ·The complete investor list: 12 names
  • ·Watch Syntis Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 12 firms already write checks for companies like Syntis Bio. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View